3[1]Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled. JAMA 2001;285(13) :1711-1718.
4[2]Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American college of cardiology/American heart association task for practice guidelines. (Committee on the Management of Patients with Unstable Angina ) J Am CollCardiol 2000;36(3) :970-1062.
5[4]Celermajer DS, Sorensen KE, Gooch VM, et al. Non invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992 ;340(8828): 1111-1115.
6[5]Hirschfield GM, Pepys MB. C-reactive protein and cardiovas cular disease: new insights form an old molecule.QJM 2003;96(11):793-807.
7[6]Tamai O, Matsuoka H, Itabe H, et al. Single LDL apheresis improves ehdothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997;95(1) :76-82.
8[7]Kaesemeyer WH, Caldwell RB, Huang J, et al. Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering action. J Am Coll cordiol 1999 ;33(1) :234-241.
9[8]Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patient with average cholesterol levels, Cholesterol and Recurrent Events trial Investigators. N Engl J Med 1996; 335(14):1001-1009.
10[10]Water DD, Azar RP. Should intensive cholesterol lowering play a role in the management of acute coronary syndromes?Am J Cardiol 2000;86(Suppl) :35J-43J.
